In today’s Pharmaceutical Executive Daily, we cover Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics, ongoing legal and market implications of the Most Favored Nation drug pricing proposal, and the FDA’s approval of Libtayo as an adjuvant therapy for cutaneous squamous cell carcinoma.

Pharmaceutical Executive Daily: Most Favored Nation Order's Evolving Landscape

<div>The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and <a href="http://PharmExec.com">PharmExec.com</a> to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. </div>

Science

Life Sciences

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and <a href="http://PharmExec.com" rel="noopener noreferrer">PharmExec.com</a> to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.&nbsp;

Share Pharmaceutical Executive Daily: Most Favored Nation Order's Evolving Landscape

Sign up to save your podcasts

Pharmaceutical Executive Daily: Most Favored Nation Order's Evolving Landscape

Pharmaceutical Executive Daily: Most Favored Nation Order's Evolving Landscape

More shows like Pharmaceutical Executive

Global News Podcast

WSJ Your Money Briefing

WSJ What’s News

The McKinsey Podcast

WSJ Tech News Briefing

HBR IdeaCast

WSJ Minute Briefing

Bold Names

The Readout Loud

Thoughts on the Market

The Journal.

BioCentury This Week

Biotech Hangout

The So What from BCG

WSJ's Take On the Week